Sonoma Biotherapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sonomabio.com

Founded Year

2020

Stage

Series B | Alive

Total Raised

$335M

Last Raised

$265M | 1 yr ago

About Sonoma Biotherapeutics

Sonoma Biotherapeutics develops adoptive Treg therapies cell for autoimmune and degenerative diseases.

Sonoma Biotherapeutics Headquarter Location

400 E. Jamie Ct Suite 250

San Francisco, California, 94080,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sonoma Biotherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sonoma Biotherapeutics is included in 3 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

D

Diabetes

1,750 items

Latest Sonoma Biotherapeutics News

Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases

Jun 8, 2022

Phase 1 study expected to be initiated in Q3 2022 June 08, 2022 08:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif. & SEATTLE--( BUSINESS WIRE )-- Sonoma Biotherapeutics , an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 study of SBT115301 in healthy participants. SBT115301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease. “This IND clearance is an important milestone as we move our programs into clinical development, including the SBT115301 program, which is a key piece of our therapeutic strategy,” said Jeff Bluestone, Ph.D., Co-Founder and CEO of Sonoma Biotherapeutics. “We aim to restore immune tolerance with therapies that impact both sides of the immune balance— combining engineered Treg cell therapies with a biologic that can deplete and inactivate Teff cells. Our combinatorial approach holds the potential to transform the way we treat autoimmune and inflammatory diseases.” Sonoma Biotherapeutics is pioneering Treg cell therapies alone and in combination with a Teff modulating therapy. The loss of immune system balance is correlated with Treg-resistant Teff cells. SBT115301 is a CD2-binding fusion protein that resets the microenvironment by selectively depleting and inactivating these Teff cells at the site of disease. As a combination therapy, SBT115301 is designed to pre-condition patients for optimal treatment with Treg cell therapies. About Sonoma Biotherapeutics Sonoma Biotherapeutics is an immune tolerance company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information visit www.sonomabio.com and follow on Twitter and LinkedIn . Contacts

Sonoma Biotherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sonoma Biotherapeutics Rank

  • When was Sonoma Biotherapeutics founded?

    Sonoma Biotherapeutics was founded in 2020.

  • Where is Sonoma Biotherapeutics's headquarters?

    Sonoma Biotherapeutics's headquarters is located at 400 E. Jamie Ct, San Francisco.

  • What is Sonoma Biotherapeutics's latest funding round?

    Sonoma Biotherapeutics's latest funding round is Series B.

  • How much did Sonoma Biotherapeutics raise?

    Sonoma Biotherapeutics raised a total of $335M.

  • Who are the investors of Sonoma Biotherapeutics?

    Investors of Sonoma Biotherapeutics include 8VC, ARCH Venture Partners, JDRF T1D Fund, Lilly Asia Ventures, Alexandria Venture Investments and 22 more.

  • Who are Sonoma Biotherapeutics's competitors?

    Competitors of Sonoma Biotherapeutics include Quell Therapeutics.

You May Also Like

TxCell Logo
TxCell

TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.

Tmunity Therapeutics Logo
Tmunity Therapeutics

Tmunity Therapeutics develops T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors.

T
TRACT Therapeutics

TRACT Therapeutics is developing a therapy dedicated to organ transplant success. The therapy involves the isolation and expansion of a patient's own naturally occurring T regulatory cells, known as Tregs.

Q
Quell Therapeutics

Quell Therapeutics is a London-based biotech company developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases.

Caladrius Biosciences Logo
Caladrius Biosciences

Caladrius Biosciences is a clinical-stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The company was founded in 2006 and is based in Basking Ridge, New Jersey.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.